These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23032961)

  • 21. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
    Langkilde LK; Bergholdt Asmussen M; Overgaard M
    J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service.
    Atay JK; Fiumara K; Piazza G; Fanikos J; Goldhaber SZ
    Clin Appl Thromb Hemost; 2012; 18(2):181-4. PubMed ID: 21873358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation.
    Micieli A; Bennell MC; Pham B; Krahn M; Singh SM; Wijeysundera HC
    J Am Heart Assoc; 2014 Sep; 3(5):e001031. PubMed ID: 25227405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
    Fanikos J
    J Med Econ; 2013 Oct; 16(10):1190-2. PubMed ID: 23919663
    [No Abstract]   [Full Text] [Related]  

  • 25. Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
    Heart Advis; 2011 Jan; 14(1):4. PubMed ID: 22973590
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
    Chang AM; Ho JC; Yan BP; Yu CM; Lam YY; Lee VW
    Clin Cardiol; 2013 May; 36(5):280-5. PubMed ID: 23494609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
    Kansal AR; Sharma M; Bradley-Kennedy C; Clemens A; Monz BU; Peng S; Roskell N; Sorensen SV
    Thromb Haemost; 2012 Oct; 108(4):672-82. PubMed ID: 22898892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
    You JH; Tsui KK; Wong RS; Cheng G
    PLoS One; 2012; 7(6):e39640. PubMed ID: 22745801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
    Rahme RJ; Bernstein R; Batjer HH; Bendok BR
    Neurosurgery; 2011 Feb; 68(2):N16-7. PubMed ID: 21654569
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.
    Clemens A; Peng S; Brand S; Brueckmann M; Kansal A; Lim J; Noack H; Sander S; Sorensen S
    Am J Cardiol; 2014 Sep; 114(6):849-55. PubMed ID: 25103918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
    Calvo Romero JM
    Rev Clin Esp; 2011 Mar; 211(3):142-6. PubMed ID: 21371701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
    Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
    Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabigatran for stroke prevention in all patients with atrial fibrillation?
    Hunchuck JE; Lake JD
    Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
    [No Abstract]   [Full Text] [Related]  

  • 34. Atrial fibrillation--not so NICE in Ireland!
    Collins DR; Coughlan T
    Ir Med J; 2012; 105(7):229-31. PubMed ID: 23008880
    [No Abstract]   [Full Text] [Related]  

  • 35. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.
    Faria R; Spackman E; Burch J; Corbacho B; Todd D; Pepper C; Woolacott N; Palmer S
    Pharmacoeconomics; 2013 Jul; 31(7):551-62. PubMed ID: 23620211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stroke prevention in atrial fibrillation.
    Wagenaar P
    Cardiovasc J Afr; 2011; 22(2):105. PubMed ID: 21556458
    [No Abstract]   [Full Text] [Related]  

  • 37. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.
    Pink J; Lane S; Pirmohamed M; Hughes DA
    BMJ; 2011 Oct; 343():d6333. PubMed ID: 22042753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
    Pink J; Pirmohamed M; Lane S; Hughes DA
    Clin Pharmacol Ther; 2014 Feb; 95(2):199-207. PubMed ID: 24067746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
    Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
    Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.